[Standard and experimental therapy of cutaneous T-cell lymphoma].
Cutaneous T-cell lymphoma represent a heterogeneous group of diseases characterized by skin invasion of monoclonal T-lymphocytes. These cutaneous T-cell lymphomas are divided into 3 groups based on clinical, histological and immunohistological characteristics: Indolent with a survival time of over 10 years, aggressive with a survival time less than 10 years and provisional (EORTC classification). Standard treatments such as PUVA, total skin electron beam, methotrexate, polychemotherapy regimens, retinoids and photopheresis have been used for years. Bexarotene is a newly registered drug. To achieve better response rates, several new drugs are being evaluated in clinical trails, including imiquimod, denileukon-diftitox, liposomal doxorubicin, adeno-interferon-gamma and various combination approaches.
Beyeler
M
M
Dermatologische Klinik Universitätsspital Zürich, Zürich.
Dummer
R
R
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077610:Bexarotene; D002699:Chlorambucil / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D011701:PUVA Therapy; D017893:Photopheresis; D011241:Prednisone / Q000627:therapeutic use; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D011994:Recombinant Proteins; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000145:classification / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000634:Aminoquinolines; D000903:Antibiotics, Antineoplastic; D016588:Anticarcinogenic Agents; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D002699:Chlorambucil; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000077610:Bexarotene; D000077271:Imiquimod; D011241:Prednisone; D008727:Methotrexate